RedHill Biopharma: First patient enrolled in government-supported COVID-19 study

RedHill Biopharma announced that the first patient has been enrolled in the Austere environments Consortium for Enhanced Sepsis Outcomes’ U.S. government-supported PROTECT multinational platform trial for early COVID-19 outpatient treatment. RHB-107 is the first drug being tested in this platform study. Funded through non-dilutive external sources, including the U.S. Department of Defense, the PROTECT study is expected to be conducted in the U.S., Thailand, Ivory Coast, South Africa and Uganda, and is estimated to be completed by the end of 2024.